Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ventdusud / Shutterstock.com We’re starting off the week with a breakdown of the biggest pre-market stock movers for Monday morning! Moving stocks is news out of China, an acquisition deal, as well as...
-- In the Study, VAX-24 Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20™ (PCV20) at All Doses Studied -- -- All 24 Serotypes of VAX-24 at Conventional 2.2mcg PCV Dose Met or Exceeded Regulatory Immunogenicity Standards -- ...
SAN CARLOS, Calif., Oct. 23, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tom...
Vaxcyte ( NASDAQ: PCVX ) has appointed Mark Wiggins as chief business officer and Jakub Simon as chief medical officer . Wiggins was most recently CBO at TRACON Pharmaceuticals ( TCON ). Simon was a Vaxcyte consultant and before then, director of...
-- Vaxcyte has Appointed Mark Wiggins, M.B.A. as Chief Business Officer and Jakub Simon M.D., M.S. as Chief Medical Officer as the Company Prepares to Enter Next Phase of Growth -- SAN CARLOS, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-s...
-- Company Expects to Announce Topline Data from Study in Adults 65 Years and Older in the First Half of 2023 -- -- Vaxcyte Remains on Track to Announce Topline Data from the Phase 1 and Phase 2 Portions of the VAX-24 Proof-of-Concept Study in Adults Aged 18-64 in October ...
Vaxcyte press release ( NASDAQ: PCVX ): Q2 net loss was $48.5 million, compared to $23.7 million for the same period in 2021. Cash, cash equivalents and investments were $361.4 million as of June 30, 2022, compared to $273.1 million as of December 31, 2021. For furth...
-- Completed Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults -- -- Announcement of Topline Results from the Phase 1 and Phase 2 Portions of the VAX-24 Proof-of-Concept...
Clinical-stage biotech Vaxcyte, Inc. ( NASDAQ: PCVX ) announced on Thursday that the FDA awarded the Fast Track designation to company’s pneumococcal conjugate vaccine (PCV) candidate VAX-24 in adults aged 18 years and older. VAX-24 is a 24-valent PCV candidate design...
-- Company Receives FDA Fast Track Designation for VAX-24 in Adults -- -- Vaxcyte Completes Successful Pre-IND Meeting with FDA Regarding VAX-24 Pediatric Program, Supporting Path to Proceed Directly into Infants -- -- VAX-24 is 24-Valent Pneumococcal Conjugate...
News, Short Squeeze, Breakout and More Instantly...
SAN CARLOS, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed John Furey, a seasoned industry expert, to its Boa...
2024-06-23 20:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-23 06:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...